China Antihypertensive Trial in Acute Ischemic Stroke II

PHASE3CompletedINTERVENTIONAL
Enrollment

4,810

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

October 15, 2022

Study Completion Date

January 15, 2023

Conditions
Acute Ischemic Stroke
Interventions
OTHER

Early antihypertensive treatment

"The CATIS 2 trial is designed to test BP reduction strategies-early antihypertensive treatment vs. delayed antihypertensive treatment-rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial.~BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:~* Step 1 (within 24 hours after randomization): To lower systolic BP by 10-20% with an average of 15% (but systolic BP not lower than 130 mmHg and diastolic BP not lower than 80 mmHg) within the first 24 hours after randomization based on the participant's admission BP levels.~* Step 2 (within 7 days after randomization): To achieve systolic BP below 140 mmHg (but not lower than 120 mmHg) and diastolic BP below 90 mmHg (but not lower than 70 mmHg) and maintain this BP level afterward."

OTHER

Delayed antihypertensive treatment

All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP \<140 mmHg (but not lower than 120 mmHg) and diastolic BP \<90 mmHg (but not lower than 70 mmHg) in two weeks. A BP check-up visit will be conducted in two weeks. If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.

Trial Locations (1)

100050

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Tiantan Hospital

OTHER

collaborator

Soochow University

OTHER

lead

Tulane University

OTHER

NCT03479554 - China Antihypertensive Trial in Acute Ischemic Stroke II | Biotech Hunter | Biotech Hunter